Proptosis

KOLOA, Hawaii — Effective management of thyroid eye disease requires a focus on mitigating modifiable risk factors, according to a presenter at Hawaiian Eye 2025.

Linsitinib, an oral small molecule under development for the treatment of thyroid eye disease, demonstrated proptosis reduction and safety in the phase 2b/3 LIDS trial, according to a press release from Sling Therapeutics.

A 48-year-old man presented to the Lahey Eye Clinic as a new patient for care after recent head trauma while he was in another state.

A phase 3 clinical trial of veligrotug, an anti-insulin-like growth factor-1 receptor antibody, met primary and secondary endpoints involving proptosis, clinical activity scores and diplopia for the treatment of chronic thyroid eye disease.

A decrease in the number of orbital decompression surgeries in patients with thyroid eye disease may be attributed to the introduction of teprotumumab treatment, according to a study published in Canadian Journal of Ophthalmology.

Less than 25% of patients with thyroid eye disease who underwent a full course of treatment with Tepezza required re-treatment, according to a study published in Ophthalmology.

A 42-year-old man with no significant medical history presented initially in the emergency department of an outside hospital with a 2-week history of progressive bilateral nasal congestion, facial pain and pressure.

WAILEA, Hawaii — In this Healio Video Perspective from Hawaiian Eye 2024, Andrew G. Lee, MD, discusses neuro-ophthalmic mimics of thyroid eye disease.

Adults with long-standing thyroid eye disease and low clinical activity scores had greater reductions in proptosis with teprotumumab compared with placebo, according to data published in The Journal of Clinical Endocrinology & Metabolism.

A 90-year-old woman was referred by her ophthalmologist to the emergency department at our institution following several weeks of discomfort and a “pinching” sensation in the left eye.